An adenovirus-vector COVID-19 candidate vaccine.

Phase of research

Potential treatment - clinical evidence

How it helps


Drug status


Supporting references
Contradictory references
Clinical trials

General information

Ad5-nCoV is a COVID-19 candidate vaccine being developed by CanSino Biological Inc. and the Beijing Institute of Biotechnology. It is an Adenovirus Type 5 Vector type of candidate vaccine. It is based on the non-replicating viral vector platform, which is also used for non-COVID-19 candidates, such as Ebola. Currently, this COVID-19 candidate vaccine is being evaluated in Phase I and Phase II clinical trials.

Supporting references

Link Tested on Impact factor Notes Publication date DB entry date
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
DNA Animal model
BALB/c mice; ferrets 12.12

Adenovirus vaccine for mucosal delivery carrying host-optimized SARS-CoV-2 spike protein gene elicited strong humoral and cellular immune responses in mice and protected them from mouse-adapted SARS-CoV-2 infection in upper and lower respiratory tract. The vaccine also protected ferrets form upper respiratory tract infection by the wild type virus.

Aug/14/2020 Aug/29/2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial healthy adults

safe, and induced significant immune responses in the majority of recipients after a single immunisation

Jul/20/2020 Aug/05/2020
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial healthy adults

The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination.

May/22/2020 May/25/2020
DRAFT landscape of COVID-19 candidate vaccines – 26 March 2020 in vitro Mar/26/2020 Apr/03/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT05169008 A Study to Evaluate the Safety and Immunogenicity of a 2-dose Regimen COVID-19 Vaccine in Children and Adolescents Aged 6-17 Years Not yet recruiting Phase 3 Feb/20/2022 Aug/20/2023
NCT05204589 Heterologous Boost Immunization With an Aerosolised Ad5-nCoV After Two-dose Priming With an Inactivated SARS-CoV-2 Vaccine Recruiting Phase 3 Jan/22/2022 Sep/01/2022
NCT05124561 Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE) Not yet recruiting Phase 3 Dec/15/2021 Aug/20/2022
NCT05043259 Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming With an Inactivated SARS-CoV-2 Vaccine Recruiting Phase 1|Phase 2 Sep/13/2021 May/01/2022
NCT05005156 Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older. Recruiting Phase 2 Jun/24/2021 Sep/30/2022
NCT04916886 A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups. Recruiting Not Applicable Jun/03/2021 Aug/01/2022
NCT04552366 A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Active, not recruiting Phase 1 Sep/29/2020 Jun/30/2021